How a collaborative approach is key to faster drug development




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: How a collaborative approach is key to faster drug development
Released on: March 15, 2017. © PharmaVentures Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    The centre of innovative medical discoveries.
  • Summary
  • Transcript
  • Participants
  • Company
The centre of innovative medical discoveries. The Medicines Discovery Catapult is a new, national centre of applied R&D expertise to promote and support innovative, fast-to-patient drug discovery in the UK through collaborative projects across the community. MDC work with biopharma companies of all sizes, translational researchers, technology experts, patient groups and the contract research and finance sectors to help transform great ideas into commercial products and services for the wider health and wealth of the country. By developing and validating new ways of discovering new medicines, and promoting key talent and expertise across sectors, MDC can help the UK maintain its heritage position as a global leader in this key industry. Find out more with Adrian Dawkes of PharmaVentures, as he discusses the significance of having patients in the centre of drug discovery with Chris Molloy, CEO of MDC.
The centre of innovative medical discoveries. The Medicines Discovery Catapult is a new, national centre of applied R&D expertise to promote and support innovative, fast-to-patient drug discovery in the UK through collaborative projects across the community. MDC work with biopharma companies of all sizes, translational researchers, technology experts, patient groups and the contract research and finance sectors to help transform great ideas into commercial products and services for the wider health and wealth of the country. By developing and validating new ways of discovering new medicines, and promoting key talent and expertise across sectors, MDC can help the UK maintain its heritage position as a global leader in this key industry. Find out more with Adrian Dawkes of PharmaVentures, as he discusses the significance of having patients in the centre of drug discovery with Chris Molloy, CEO of MDC.
Chris has over 25 years international Executive and Board experience across multiple areas of Medicines Discovery. He began his career in discovery biology at Glaxo, and has delivered transformational change across research by implementing specialist automation and informatics systems. He moved into biotech as Chief Operating Officer of MerLion Pharmaceuticals in Singapore. During his tenure, MerLion raised significant international finance and advanced two novel antibacterials into clinical development. On returning to the UK in 2008, he became VP Corporate Development and Marketing at IDBS, a high-growth international software company focussed on improving R&D and healthcare organisations through better access to data. This included the creation of the UK’s first stratified medicine informatics platform, co-funded with Innovate UK. He was previously CEO of RSA, a senior-level global Talent Advisory firm specialising in Life Sciences. Chris has held many Board and advisory roles and acts as CSO for KFLP Biotech LLP, a virtual drug discovery company focused on new treatments for HIV.
The Medicines Discovery Catapult is a new, national centre of applied R&D expertise to promote and support innovative, fast-to-patient drug discovery in the UK through collaborative projects across the community. MDC work with biopharma companies of all sizes, translational researchers, technology experts, patient groups and the contract research and finance sectors to help transform great ideas into commercial products and services for the wider health and wealth of the country. By developing and validating new ways of discovering new medicines, and promoting key talent and expertise across sectors, MDC can help the UK maintain its heritage position as a global leader in this key industry.